丙丁酚治疗非增殖性糖尿病视网膜病变的临床观察.pdfVIP

Hans Journal of Ophthalmology 眼科学, 2014, 3, 13-18 Published Online June 2014 in Hans. /journal/hjo /10.12677/hjo.2014.32003 Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy Suping Jiang, Zhongping Chen Liuzhou Worker’s Hospital, Liuzhou Email: yunping1314@126.com nd nd th Received: May 2 , 2014; revised: Jun . 2 , 2014; accepted: Jun . 12 , 2014 Copyright © 2014 by authors and Hans Publishers Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). /licenses/by/4.0/ Abstract Objective: To observe the clinical efficacy of probucol for nonproliferative diabetic retinopathy (NPDR). Methods: 68 patients with nonproliferative diabetic retinopathy (NPDR) were studied from Jan. 2012 to Aug. 2013. These patients were divided into four groups. Group A consisted of 17 patients receiving enhanced therapy and probucol; Group B consisted of 17 patients receiving enhanced therapy; Group C consisted of 17 patients receiving regular therapy and probucol; Group D consisted of 17 patients receiving regular therapy. Group A and Group C were given probucol of 0.375 g twice per day. All patients were followed up for average 11.58 ± 0.17 months. The changes of best corrected visual acuity, fundus, total cholesterol (TC), low density lipoprotein- cholesterol (LDL-C) before therapy and one year after therapy were observed. Results: 1) The fundi of Group A and Group C were significantly improved (P 0.05), and there was no significant difference between the fundi of Group A and of Group C after therapy (P 0.05); but the d